Vanguard Group Inc Coherus Bio Sciences, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 10,321,107 shares of CHRS stock, worth $12.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,321,107
Previous 10,570,515
2.36%
Holding current value
$12.3 Million
Previous $7.72 Million
119.36%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CHRS
# of Institutions
125Shares Held
54.7MCall Options Held
291KPut Options Held
120K-
Black Rock Inc. New York, NY11.8MShares$14 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$6.07 Million0.38% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.61 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA2.74MShares$3.26 Million0.0% of portfolio
-
State Street Corp Boston, MA2.22MShares$2.65 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $92.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...